[{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Stemline Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Stemline Therapeutics \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant Dihydrochloride","moa":"Estrogen receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"MEDSIR","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Stemline Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Stemline Therapeutics \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stemline Therapeutics \/ Stemline Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Stemline Therapeutics \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Stemline Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Stemline Therapeutics \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0.68000000000000005,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"Injection","sponsorNew":"Stemline Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0.68000000000000005,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"Injection","sponsorNew":"Stemline Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Jacqueline Garcia | Break Through Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stemline Therapeutics \/ Jacqueline Garcia | Break Through Cancer Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Stemline Therapeutics \/ Jacqueline Garcia | Break Through Cancer Foundation"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Stemline Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Stemline Therapeutics \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MEN2312","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SL-901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Stemline Therapeutics","amount2":0.51000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Stemline Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Stemline Therapeutics \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Stemline Therapeutics","amount2":0.56999999999999995,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.56999999999999995,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Stemline Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Stemline Therapeutics \/ Stemline Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Stemline Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Tagraxofusp is a Protein drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 29, 2025

                          Lead Product(s) : Tagraxofusp

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Jacqueline Garcia | Break Through Cancer Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Under the licensing agreement, Stemline will hold the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $20.0 million

                          January 10, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Insilico Medicine

                          Deal Size : $570.0 million

                          Deal Type : Licensing Agreement

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : MEN2312 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : MEN2312

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Tagraxofusp is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 19, 2024

                          Lead Product(s) : Tagraxofusp

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Stanford University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Elacestrant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 09, 2024

                          Lead Product(s) : Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Tagraxofusp is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          June 13, 2024

                          Lead Product(s) : Tagraxofusp

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Everolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 24, 2024

                          Lead Product(s) : Everolimus

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : MEDSIR

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Olaparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 11, 2024

                          Lead Product(s) : Olaparib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : GBG Forschungs GmbH

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Stemline will have global rights to develop a novel KAT6A inhibitor designed using Insilico’s AI platform, targeting hormone-sensitive cancers and other oncology indications.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $12.0 million

                          January 04, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : Insilico Medicine

                          Deal Size : $512.0 million

                          Deal Type : Licensing Agreement

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Elacestrant Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 13, 2023

                          Lead Product(s) : Elacestrant Dihydrochloride

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank